The Gardasil lawsuits against Merck have effectively ended. After a federal judge dismissed more than 200 cases on preemption grounds in March 2025, the Fourth Circuit affirmed those dismissals in September 2025, and Merck agreed in October 2025 to pay more than $50 million to resolve the remaining claims without admitting liability.1Claims Journal. Merck Reaches Agreement to Settle Gardasil Litigation No Gardasil case ever reached a jury verdict, and lawyers involved in the litigation say new cases are no longer being accepted.2AboutLawsuits.com. Gardasil Lawsuits
Where the Litigation Stands in 2026
The federal multidistrict litigation, MDL No. 3036 in the Western District of North Carolina, peaked at 258 actions and had dropped to 129 active cases by April 2026.3MDL Update. MDL 3036 – Gardasil Between the March 2025 summary judgment ruling, the appellate affirmance, and the proposed settlement, the MDL has been resolved. Merck did not admit liability and continues to maintain that Gardasil is safe and effective.4Yahoo Finance. Merck Gardasil Settlement Eases Legal Concerns
If you believe a vaccine injury occurred, the civil courthouse door is closed for practical purposes. The remaining route is the federal Vaccine Injury Compensation Program, discussed below, and even that route has a strict filing deadline that the appeals court treated as a hard barrier.
What Plaintiffs Claimed Gardasil Caused
The two headline injury categories were postural orthostatic tachycardia syndrome (POTS), an autonomic nervous system disorder that causes dizziness, fainting, and rapid heart rate, and premature ovarian insufficiency (POI), which can produce early menopause and infertility in young women.5AboutLawsuits.com. Gardasil Settlement: $50M Payout by HPV Vaccine Manufacturer Plaintiffs also alleged Guillain-Barré syndrome, complex regional pain syndrome, chronic fatigue syndrome, small fiber neuropathy, multiple sclerosis, autoimmune hepatitis, and seizures, among other autoimmune and neurological conditions.6Lawsuit Information Center. Gardasil HPV Vaccine Lawsuit
The core legal theory was failure to warn: plaintiffs argued Merck should have added label warnings about POTS and POI. A related fraudulent concealment claim alleged Merck hid safety data. Some plaintiffs also raised design-defect claims and challenged Merck’s marketing practices.6Lawsuit Information Center. Gardasil HPV Vaccine Lawsuit
Why the MDL Was Dismissed
On March 10 and 11, 2025, Judge Kenneth D. Bell granted Merck’s motion for summary judgment across the bellwether cases and, by prior agreement, extended the ruling to the broader pool of MDL cases alleging the same injuries.7Dechert LLP. Federal Preemption Shuts Down Failure to Warn Claims in Gardasil Litigation The ruling rested on two grounds.
The first was federal preemption. FDA regulations allow a manufacturer to add new warnings unilaterally only when it possesses “newly acquired information” showing reasonable evidence of a causal association between the product and the injury. Judge Bell found the evidence plaintiffs cited fell far short of that standard. By 2013, more than 100 million doses of Gardasil had been administered worldwide, yet there was only one published, verified case of POTS and four published reports of POI linked to the vaccine.8Fierce Pharma. Merck Emerges Victorious in Gardasil Safety Litigation Because Merck could not lawfully have added those warnings on its own, state-law failure-to-warn claims collapsed.
The second was a lack of causation evidence. Judge Bell wrote that “no scientist could reasonably conclude there is a causal association” between Gardasil and the alleged conditions “based on this paucity of evidence,” and warned that unwarranted vaccine warnings could discourage life-saving immunizations.8Fierce Pharma. Merck Emerges Victorious in Gardasil Safety Litigation
The Fourth Circuit Ruling
Plaintiffs appealed. On September 4, 2025, a unanimous three-judge panel of the Fourth Circuit affirmed. Chief Judge Albert Diaz, joined by Judges Paul Niemeyer and Nicole Berner, held that timely participation in the Vaccine Injury Compensation Program is a mandatory prerequisite to filing any tort suit against a vaccine manufacturer.9Fourth Circuit Court of Appeals. In Re: Gardasil Products Liability Litigation, Nos. 24-1828, 24-1831, 24-1832
The three appellants had conceded their VICP petitions were untimely, and a special master had already dismissed them. The Fourth Circuit ruled that once a special master makes a final timeliness determination, district courts cannot revisit it. The only appellate path from that determination runs through the Court of Federal Claims and the Federal Circuit, not a civil lawsuit.10Carolina Journal. Federal Appeals Court Rejects NC-Based Vaccine Lawsuits Against Merck For anyone still weighing action, the practical takeaway is that missing the VICP deadline forecloses suing Merck at all.
The $50 Million Settlement
Even after winning on the merits, Merck moved to settle. In October 2025, the company entered a proposed agreement to pay more than $50 million to resolve over 200 Gardasil cases, including cases that had already been dismissed on preemption grounds.1Claims Journal. Merck Reaches Agreement to Settle Gardasil Litigation The deal covers claims of autoimmune conditions affecting women’s hearts and reproductive systems.5AboutLawsuits.com. Gardasil Settlement: $50M Payout by HPV Vaccine Manufacturer
Merck described the settlement amount as “not material” to the company and “considerably less” than the cost of continuing to defend each case through trial.1Claims Journal. Merck Reaches Agreement to Settle Gardasil Litigation As of June 2026, the settlement was contingent on a sufficient number of claimants signing on and had not yet been finalized.5AboutLawsuits.com. Gardasil Settlement: $50M Payout by HPV Vaccine Manufacturer Per-claimant payout figures were not disclosed.
The Separate California Case
One case sat outside the MDL and the settlement structure: Robi v. Merck, filed in California state court in July 2016 by Jennifer Robi, a Pasadena woman who alleged Gardasil left her confined to a wheelchair as a teenager and caused a weakened heart. Her case had been positioned as the first major Gardasil jury trial and was scheduled for July 2026. On June 2, 2026, her attorneys filed papers dismissing the case with prejudice. The court papers did not state whether a settlement had been reached, but Merck had disclosed in February 2026 that it had entered into a “tentative accord to resolve the case before trial.”11Pasadena Now. Pasadena Woman Drops Suit vs. Merck Over Gardasil HPV Vaccine
The Vaccine Injury Compensation Program
Because Gardasil is a covered vaccine, injury claims must go through the National Vaccine Injury Compensation Program (VICP) before any civil suit, and the Fourth Circuit’s ruling makes clear that the VICP’s 36-month statute of limitations is enforced strictly.9Fourth Circuit Court of Appeals. In Re: Gardasil Products Liability Litigation, Nos. 24-1828, 24-1831, 24-1832
The program’s own numbers give a sense of the odds. As of June 2025, 991 petitions had been filed for HPV vaccine injuries over the life of the program, including 24 alleging death. Of those, 202 were compensated and 619 were dismissed. Of the 202 compensated claims, 132 came through negotiated settlement, 53 through government concession, and 13 by court decision. The program cautions that roughly 60% of its compensation payouts result from negotiated settlements in which the government has not concluded the vaccine actually caused the alleged injury; those settlements are not admissions of causation but decisions to minimize litigation costs.12Health Resources & Services Administration. VICP Data Report
Why Plaintiffs Struggled on the Science
A central problem for plaintiffs was the weight of the scientific evidence on the other side. The CDC and FDA have found no evidence that HPV vaccines cause POI, POTS, complex regional pain syndrome, Guillain-Barré syndrome, chronic fatigue syndrome, or death.13Centers for Disease Control and Prevention. HPV Vaccine Safety A 2018 cohort study of nearly 200,000 women published in Pediatrics found no statistically significant elevated risk of POI after HPV vaccination, with an adjusted hazard ratio of 0.30, and cautioned that earlier case reports suggesting a link should be “interpreted with caution.”14Centers for Disease Control and Prevention Stacks. Primary Ovarian Insufficiency and Adolescent Vaccination
The World Health Organization’s Global Advisory Committee on Vaccine Safety, reviewing data from more than 270 million distributed doses as of 2017, concluded the vaccine is “extremely safe.” Large population studies from the United States and Denmark found no causal association with CRPS, POTS, POI, or venous thromboembolism, and a WHO-commissioned systematic review of trials involving nearly 74,000 individuals found no difference in serious adverse events between vaccinated and unvaccinated groups.15World Health Organization. Human Papillomavirus Vaccines Safety
The evidence plaintiffs relied on was thinner. A 2014 article in the Journal of Investigative Medicine High Impact Case Reports documented three young women in Australia who developed POI after HPV vaccination.16National Center for Biotechnology Information. Adolescent Premature Ovarian Insufficiency Following Human Papillomavirus Vaccination A separate 2014 Utah case study described POTS symptoms after vaccination.17National Center for Biotechnology Information. HPV Vaccination and POTS Case Report A 2022 analysis published in PMC concluded that the molecular-mimicry and mouse-model studies cited in earlier Japanese HPV vaccine litigation rested on “flawed methodology”; one key mouse study by Nakajima and colleagues had been retracted, and attempts to replicate another study’s findings with larger samples had failed.18National Center for Biotechnology Information. Evaluation of Hypotheses in HPV Vaccine Litigation
That evidentiary gap is what Judge Bell relied on when he found Merck could not lawfully have added the warnings plaintiffs said were missing, and it is why the litigation ended without a single jury ever hearing a Gardasil case.